Research drives our commitment to improve outcomes for people living with #lungcancer. Find the primary manuscript from the phase 3 CheckMate 77T study published in the NEJM (NEJM Group) from lead author Dr. Tina Cascone, senior author Dr. Mariano Provencio, and co-investigators. Efficacy, safety, surgical outcomes, and HRQoL are comprehensively reported for this perioperative immunotherapy-based treatment in patients with resectable non-small cell lung cancer. Find the full manuscript here: https://bit.ly/4ajAblz #LCSM
Bristol Myers Squibb
Pharmaceutical Manufacturing
Lawrence Township, NJ 1,402,013 followers
About us
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
- Website
-
http://www.bms.com
External link for Bristol Myers Squibb
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lawrence Township, NJ
- Type
- Public Company
- Specialties
- biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
Locations
Employees at Bristol Myers Squibb
-
Bill Trebasky
Biopharmaceuticals Operations Executive
-
Mark Kaplan
Senior Director Translational Oncology
-
Lisa Filaferro, MBA, PHR
-
Lakshman Nagesh Yerramalla
Transformations Strategist, Sr. PMO Leader - Expert in envisioning and driving transformational initiatives, Building high-performance PMO
Updates
-
The FDA has granted accelerated approval for our #CARTcelltherapy to treat relapsed or refractory (R/R) follicular lymphoma (FL). We are continuing to unlock the full promise of cell therapy through our strong leadership and scientific innovation, providing personalized treatment to patients. To all who were involved in making this milestone possible, thank you for your continued dedication to patients. https://bit.ly/3WKYshy
-
-
As a board-certified dermatologist, Dr. Geeta Yadav wishes it was easier for patients to have access to dermatology specialists and #psoriasis treatment. Treating people of diverse backgrounds who have psoriasis has become a fundamental focus of her practice to ensure all patients are diagnosed quickly and correctly and receive suitable treatment. At Bristol Myers Squibb, we share Dr. Yadav's commitment to the psoriasis community. We are focused on developing solutions that aim to transform care for psoriasis patients. Learn more about psoriasis from people around the globe: https://bit.ly/3WdsmdO #EADVSymposium
-
We’re pleased to share results from our Phase 3 EMERGENT-3 clinical trial in adults with schizophrenia was awarded the Clinical Trial Results of the Year award by Citeline. With our recently expanded neuroscience pipeline, we’re committed to addressing significant unmet needs of people living with psychiatric conditions like schizophrenia.
Congratulations to Karuna Therapeutics – A Bristol Myers Squibb Company for winning the Clinical Trial Result of the Year award, sponsored by Bioforum! #CitelineAwards https://ow.ly/wf4q50RzcE7
-
-
We are dedicated to bringing innovative treatment options to cardiovascular patients, and the inclusion of our first-in-class treatment for adults living with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the AHA/ACC/AMSSM/HRS/PACES/SCMR guideline is an important update in patient care. The guidelines are a vital resource for cardiologists. This update is a testament to our unwavering commitment to addressing this overlooked condition. Learn more about why this is significant for the HCM community: https://bit.ly/3yfmSp1 #Cardiovascular #HypertrophicCardiomyopathy
-
-
We're pleased to share the Healthcare Businesswomen’s Association named our colleague Marisa Dolled-Filhart as a 2024 Luminary and Jeanette Wilson and Samira Merali as 2024 Rising Stars for outstanding leadership and advancing gender equity in healthcare. Learn more about our #HBAWOTY24 honorees: https://bit.ly/4boQnDm
-
-
A keynote about AANHPI health equity for patients. Professional development panels on creating change without comprising self-care. A virtual book club exploring female leadership. Our #AANHPI Heritage Month events, led by the Pan-Asian Network (PAN)’s Jennifer F. Rasing, embody themes of exPANded boundaries, elevated horizons and embracing identities. Join us in celebrating our AANHPI colleagues’ distinctive heritages and their work to advance health equity and drive our value of inclusion year-round.
-
-
Our extensive experience in autoimmune diseases and cell therapy drives our commitment to reshaping the treatment landscape for patients. This #LupusAwarenessMonth, Ashley Koegel shares how we’re building upon our legacy in #CARTCellTherapy and #immunology to drive cutting-edge research that has the potential to transform the treatment paradigm for patients with severe and progressive lupus. #DecodedByBMS
Bringing the science of cell therapy into autoimmune diseases
Bristol Myers Squibb on LinkedIn
-
Stroke is a leading cause of death and serious disability worldwide, which is why we’re pursuing transformational research for individuals who are at elevated risk. Our comprehensive Phase 3 Librexia program in collaboration with Johnson & Johnson Innovative Medicine aims to advance research for the prevention of stroke and help address the gap in unmet needs in thrombosis management. #StrokeMonth
-
Affiliated pages
Similar pages
Browse jobs
Stock
BMY
NYSE
20 minutes delay
$44.19
-0.36 (-0.808%)
- Open
- 44.47
- Low
- 43.68
- High
- 44.51
Data from Refinitiv
See more info on